A novel dual agonist of EP3 and FP receptors for OAG and OHT: Safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 13, 2015, Pages 7963-7970

  Suto, Fumitaka ^a   Rowe Rendleman, Cheryl L ^a   Ouchi, Takafumi ^a   Jamil, Alam ^a   Wood, Andrew ^a   Ward, Caroline L ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Healthy volunteers; Ocular hypertension; ONO 9054; Open angle glaucoma; Sepetoprost

Indexed keywords

ANTIGLAUCOMA AGENT; CARRIER PROTEINS AND BINDING PROTEINS; DRUG METABOLITE; PLACEBO; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN F RECEPTOR; SEPETOPROST; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ONO-AG-367; OXEPINE DERIVATIVE; PROPAN-2-YL 4-(6-(4-(2,5-DIFLUOROPHENOXY)-3-HYDROXYBUT-1-EN-1-YL)-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOATE; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; OPHTHALMOSCOPY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TANDEM MASS SPECTROMETRY; VISUAL ACUITY; AGONISTS; CLINICAL TRIAL; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULAR HYPERTENSION; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADULT; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OXEPINS; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; YOUNG ADULT;

EID: 84950341332     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-18166     Document Type: Article

References (20)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol. 2004;15:102-106.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study (OHTS): a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713, discussion: 829-830.
4. Leske MC, Heijl A, Hyman L, et al.; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-1972.
5. The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
6. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
7. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48-56.
8. Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study (OHTS): baseline factors that predict the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
9. Anderson DR. Collaborative Normal Tension Glaucoma Study. Curr Opin Ophthalmol. 2003;14:86-90.
10. Woodward DF, Krauss AH, Nilsson SF. Bimatoprost effects on aqueous humor dynamics in monkeys. J Ophthalmol. 2010; 2010:926192.
11. Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma. 2005;14:70-73.
12. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43: 1475-1487.
13. Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009;25:8.
14. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Current Med Res Opin. 2006;22:971-976.
15. Lui JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389-395.
16. Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD; AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302-307.
17. Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015;56: 2547-2552.
18. Hedner J, Svedmyr N, Lunde H, Mandahl A. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol. 1997;41(suppl 2):S111-S115.
19. Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447-456.
20. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145-152.